Nov Oct

Executive Summary
For Jan-23
Operations Progress Review Financials Progress Review

Patients Transfusions MoM Income & Expenditure MoM

Jan-23 Dec-22 Variance Jan-23 Dec-22 Variance

Thalassemia Patient Treated 345 366 -6%

Total Patients 271 271 0% Income 2,201,750 4,386,519 -50%

Addition/Deletions-Patients 0 0 0 Thalassemia Direct-Operations 1,929,057 1,394,117 38%

Thalassemia In-Direct-Operations 1,429,620 1,247,548 15%

Administrative Expenses-Thal 40,395 51,975 -22%

Patients Key Performance Indicators Gross Surplus /(Deficits) (1,197,322) 393,873 -404%

Total Cost Per Transfusion 10,757 9,157 17% A&G-Marketing & Non-Cash Expenses 271,530 605,675 -55%

Per Patient Direct Operational Cost 52% 5,591 3,809 47% 3,670,602 3,299,315 11%
Net Surplus/(Deficit)
Per Patient In-Direct Operational Cost 40% 4,261 3,551 20% (1,468,852) 1,087,204 -235%

Administrative Expenses-Thal 1% 117.09 142 -18%

A&G-Marketing & Non-Cash Expenses 7% 787 1,655 -52%

Net Surplus/(Deficit) -40% (4,258) 2,971 -243%

Funds Position MoM

Jan-23 Dec-22 Variance

Meezan Bank Limited 1,018,925 1,319,333 -23%

Management Commentary JS Bank Limited 8,391,041 8,209,176 2%
INCOME Zakat & TDR's Interest Income mainly -TDRs Matured 31-Dec-22 (1M) BankIslami Pakistan Limited 4,279,042 34,684,564 -88%
In-Direct FBR Tax Charges and Demand Notices Dubai Islamic Bank Limited (PKR) 141,549 141,549 0%
CAPITAL Commitment 13Millions with the prescribed time line i.e. June-2023 Dubai Islamic Bank Limited (USD) 2,985,821 2,985,821 0%
HR No new hiring although Doctor Position Vacant Emaan Islamic Banking 130,696 497,896 -74%
UTILITIES Fine as per consumptions and K-E arrears & Tariff Short Terms Deposits-TDR's 37,000,000 4,000,000 825%
EXPENSES INGO Pre-Opening Expenses -Consultancy 100K & Sharia 30K (Mufti Salary & Fuel) Total Available Funds & Investments 53,947,074 51,838,339 4%
OTH-INCOME TDR's Profit in Dec-22 PKR-9,59,375

Checked By: Approved By:

Reviewed By:
Manager Accounts & Audit Founder & CEO
President-HIWT